Susquehanna International Group
AXSM icon

Susquehanna International Group’s Axsome Therapeutics AXSM Stock Holding History

Susquehanna International Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.3M Sell
208,900
-70,500
-25% -$12.2M ﹤0.01% 1575
2025
Q4 		$51M Buy
279,400
+6,200
+2% +$866K 0.01% 1344
2025
Q3 		$33.2M Buy
273,200
+94,900
+53% +$10.7M ﹤0.01% 1692
2025
Q2 		$18.6M Sell
178,300
-126,000
-41% -$13.3M ﹤0.01% 2088
2025
Q1 		$35.5M Sell
304,300
-43,600
-13% -$4.97M 0.01% 1251
2024
Q4 		$29.4M Buy
347,900
+97,200
+39% +$8.94M ﹤0.01% 1547
2024
Q3 		$22.5M Buy
250,700
+63,900
+34% +$5.58M ﹤0.01% 1713
2024
Q2 		$15M Buy
186,800
+29,000
+18% +$2.15M ﹤0.01% 2032
2024
Q1 		$12.6M Sell
157,800
-163,200
-51% -$13.7M ﹤0.01% 2311
2023
Q4 		$25.5M Buy
321,000
+16,100
+5% +$1.08M ﹤0.01% 1557
2023
Q3 		$21.3M Sell
304,900
-45,000
-13% -$3.36M ﹤0.01% 1674
2023
Q2 		$25.1M Sell
349,900
-26,100
-7% -$1.93M 0.01% 1510
2023
Q1 		$23.2M Sell
376,000
-152,700
-29% -$10M ﹤0.01% 1567
2022
Q4 		$40.8M Sell
528,700
-38,000
-7% -$2.27M 0.01% 1000
2022
Q3 		$25.3M Buy
566,700
+300,900
+113% +$15M 0.01% 1222
2022
Q2 		$10.2M Sell
265,800
-124,200
-32% -$3.93M ﹤0.01% 2179
2022
Q1 		$16.1M Sell
390,000
-65,600
-14% -$2.03M ﹤0.01% 1937
2021
Q4 		$17.2M Buy
455,600
+111,100
+32% +$4.09M ﹤0.01% 2037
2021
Q3 		$11.4M Buy
344,500
+222,900
+183% +$8.69M ﹤0.01% 2682
2021
Q2 		$8.2M Buy
121,600
+44,800
+58% +$2.69M ﹤0.01% 3196
2021
Q1 		$4.35M Sell
76,800
-45,700
-37% -$3.21M ﹤0.01% 4188
2020
Q4 		$9.98M Sell
122,500
-66,400
-35% -$4.97M ﹤0.01% 2497
2020
Q3 		$13.5M Buy
188,900
+18,900
+11% +$1.47M ﹤0.01% 1869
2020
Q2 		$14M Sell
170,000
-103,700
-38% -$7.98M ﹤0.01% 1770
2020
Q1 		$16.1M Sell
273,700
-72,500
-21% -$5.91M 0.01% 1330
2019
Q4 		$35.8M Buy
346,200
+92,900
+37% +$3.75M 0.01% 1007
2019
Q3 		$5.13M Buy
253,300
+20,100
+9% +$516K ﹤0.01% 2693
2019
Q2 		$6M Buy
233,200
+111,200
+91% +$2.23M ﹤0.01% 2474
2019
Q1 		$1.74M Buy
122,000
+105,200
+626% +$977K ﹤0.01% 3977
2018
Q4 		$47K Buy
+16,800
New +$55.3K ﹤0.01% 8507
2018
Q3 		– Sell
-10,000
Closed -$32K – 9185
2018
Q2 		$32K Buy
+10,000
New +$31K ﹤0.01% 9359
2018
Q1 		– Sell
-36,900
Closed -$207K – 9291
2017
Q4 		$207K Buy
+36,900
New +$186K ﹤0.01% 8222

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group's AXSM Position: Q1 2026 in Review

Susquehanna International Group increased its Axsome Therapeutics (AXSM) stake by 58% in Q1 2026, buying an estimated $3M and bringing the position to 47,198 shares worth $7.98M. The position accounts for ﹤0.01% of the portfolio, ranked #3467.

Susquehanna International Group first reported a position in AXSM in Q1 2016 and has held it in 32 quarters since. The position peaked at $52M in Q4 2019. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Susquehanna International Group held 47,198 shares of Axsome Therapeutics worth $7.98M as of Q1 2026.
  • Susquehanna International Group bought 17,357 Axsome Therapeutics shares in Q1 2026, an estimated $3M.
  • Axsome Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3467 holding.
  • Susquehanna International Group first reported a position in Axsome Therapeutics in Q1 2016 and has held it in 32 quarters since.
  • Susquehanna International Group's Axsome Therapeutics position peaked at $52M in Q4 2019.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.